covers all major European markets except the British Isles and the
countries of Scandinavia. Discussions are underway to license Zingo in
those and in other major markets. Anesiva also signed an exclusive
marketing and distribution agreements with Green Vision Company for
major markets in the Middle East.
-- Publications in peer-reviewed journals on Zingo clinical trials, and
critical findings presented at medical meetings from market research
associated with the importance of treating IV pain, continue to
reinforce the need for a fast onset-of-action topical local anesthetic.
A recent survey of more than 2,000 pediatric nurses showed that nearly
all agree that inserting an IV line into a fearful, anxious child can
be challenging -- a situation that is encountered 76% of the time. The
nurses indicated that, although topical local anesthetics (TLAs) would
be beneficial in this setting, they are used less than a third of the
time. Barriers to use include slow onset of action (20 minutes or more)
and treatment delays, among others. Nearly all survey participants
(92%) agreed that patients would benefit from the use of a fast-acting
TLA for peripheral venous access procedures. The results of the survey,
which was sponsored by Anesiva, will be presented tomorrow at the
annual meeting of the American Pain Society.
-- The Phase 3 clinical development program was initiated with two pivotal
trials evaluating Adlea in patients undergoing total knee replacement
surgery and in patients undergoing bunionectomy surgery. These two
pivotal trials, along with supporting Phase 2 trials in other surgical
settings, are intended to support a broad product label for Adlea for
|SOURCE Anesiva, Inc.|
Copyright©2008 PR Newswire.
All rights reserved